BD Biosciences, a segment of BD (Becton, Dickinson and Company), launched the BD UltraPool HLM 150 reagent that consists of human liver microsomes (HLM) for use in in vitro ADME (absorption, distribution, metabolism, and excretion) drug discovery screening and development.
“BD Biosciences is committed to addressing the needs of pharmaceutical researchers,” said Charles Crespi, Ph.D., Vice President of Discovery Biologicals, BD Biosciences. “This new reagent will allow scientists to maintain consistent, high-quality results in their assays and avoid the arduous task of qualifying new lots of reagents.”
Cytochromes P450 (CYPs) are key drug metabolizing enzymes. However, CYP expression among individuals is highly variable. When performing ADME assays, it is critical to minimize the variability due to reagents in order to observe the difference in performance among drug candidates. BD UltraPool HLM 150 was developed to offer researchers a high degree of lot-to-lot consistency for CYP enzyme activity.
The BD UltraPool HLM 150 reagent helps ensure reliability in experimental results in multi-site and multi-year programs by delivering reproducible data across multiple drug-metabolizing enzymes when compared with reagents prepared from smaller pools of donors and/or prepared to lower standards. It also gives researchers access to a large donor pool (150) with equal gender mix, providing the best available representation of an “average individual’s” drug metabolism activity. The large donor pool is manufactured in large lot sizes that support multi-year drug discovery programs.